Amarin (NASDAQ:AMRN)‘s stock had its “buy” rating reissued by Cantor Fitzgerald in a report issued on Friday, TipRanks reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 105.76% from the stock’s current price.
Several other equities analysts have also recently issued reports on AMRN. The Goldman Sachs Group restated a “sell” rating and set a $5.00 price objective (down from $6.00) on shares of Amarin in a research note on Tuesday, May 18th. Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating and set a $6.25 price target on the stock in a research report on Tuesday, March 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $9.41.
Shares of AMRN stock traded down $0.02 during trading hours on Friday, hitting $4.86. 36,655 shares of the company were exchanged, compared to its average volume of 5,755,685. The firm has a 50-day moving average price of $4.95. Amarin has a one year low of $3.36 and a one year high of $9.25. The company has a market cap of $1.92 billion, a PE ratio of -97.20 and a beta of 2.25.
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Story: Gap Up Stocks
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.